Michael G. Johnson
Amgen
34 Papers
217 Citations
Michael G. Johnson is an academic researcher from Amgen. The author has contributed to research in topics: Receptor & Chemistry. The author has an hindex of 18, co-authored 34 publications.
Chat about Author
Papers
Antagonism of CXCR3 Inhibits Lung Metastasis in a Murine Model of Metastatic Breast Cancer
Tonya C. Walser,Salah Rifat,Xinrong Ma,Namita Kundu,Christopher W. Ward,Olga Goloubeva,Michael G. Johnson,Julio C. Medina,Tassie L. Collins,Amy M. Fulton +9 more
TL;DR: It is indicated that murine mammary tumor cells express CXCR3 which facilitates the development of lung metastases and for the first time that a small molecular weight antagonist of CX CR3 has the potential to inhibit tumor metastasis.
239
Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism
Béatrice Cambien,Babou Fahardine Karimdjee,Babou Fahardine Karimdjee,Peggy Richard-Fiardo,Peggy Richard-Fiardo,H. Bziouech,H. Bziouech,Robert Barthel,Robert Barthel,Marc-Alban Millet,Marc-Alban Millet,V. Martini,V. Martini,Daniel Birnbaum,J. Y. Scoazec,J. Abello,T al Saati,Michael G. Johnson,Timothy J. Sullivan,Julio C. Medina,Tassie L. Collins,Annie Schmid-Alliana,Annie Schmid-Alliana,Heidy Schmid-Antomarchi,Heidy Schmid-Antomarchi +24 more
TL;DR: It is indicated that activation of CXCR3 receptors by its cognate ligands facilitates the implantation and the progression of CRC cells within lung tissues and that inhibition of this axis decreases pulmonary metastasis of CRC in two murine tumour models.
Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs
Emmanuelle Pradelli,Babou Karimdjee-Soilihi,Babou Karimdjee-Soilihi,Michiels Jf,Jean-Ehrland Ricci,Jean-Ehrland Ricci,Marie Ange Millet,Marie Ange Millet,Fanny Vandenbos,Timothy J. Sullivan,Tassie L. Collins,Michael G. Johnson,Julio C. Medina,Eugenie S. Kleinerman,Annie Schmid-Alliana,Annie Schmid-Alliana,Heidy Schmid-Antomarchi,Heidy Schmid-Antomarchi +17 more
TL;DR: Results support the hypothesis that CXCR3 and their ligands intervene in the initial dissemination of the osteosarcoma cells to the lungs and stimulate the growth and expansion of the metastatic foci in later stages and indicate that targeting CX CR3 may specifically inhibit tumor metastasis without adversely affecting antitumoral host response.
121
Discovery and in Vivo Evaluation of Dual PI3Kβ/δ Inhibitors
Felix Gonzalez-Lopez de Turiso,Youngsook Shin,Matthew Frank Brown,Mario G. Cardozo,Yi Chen,David Fong,Xiaolin Hao,Xiao He,Kirk Henne,Yi-Ling Hu,Michael G. Johnson,Todd J. Kohn,Julia Winslow Lohman,Helen J. McBride,Lawrence R. McGee,Julio C. Medina,Daniela Metz,Kent Miner,Deanna Mohn,Vatee Pattaropong,Jennifer Seganish,Jillian L. Simard,Sharon Wannberg,Douglas A. Whittington,Gang Yu,Timothy D. Cushing +25 more
TL;DR: The optimized pyrrolopyridine analogue 63 was a potent and selective PI3Kβ/δ dual inhibitor that displayed suitable physicochemical properties and pharmacokinetic profile for animal studies and was found to be efficacious in animal models of inflammation.
59
Optimization of the heterocyclic core of the quinazolinone-derived CXCR3 antagonists.
An-Rong Li,Michael G. Johnson,Jiwen Liu,Xiaoqi Chen,Xiaohui Du,Jeffrey T. Mihalic,Jeffrey Deignan,Darin J. Gustin,Jason Duquette,Zice Fu,Liusheng Zhu,Andrew P. Marcus,Phillipe Bergeron,Lawrence R. McGee,Jay Danao,Bryan Lemon,Teresa Arazas Carabeo,Tim Sullivan,Ji Ma,Liang Tang,George Tonn,Tassie L. Collins,Julio C. Medina +22 more
TL;DR: A series of six-six and six-five fused heterocyclic CXCR3 antagonists has been synthesized and their activities evaluated in an [(125)I]-IP-10 displacement assay and an ITAC mediated in vitro cell migration assay, leading to the discovery of compounds with increased potency and improved pharmacokinetic properties that could serve as useful tools to study the role of the CX CR3 receptor in vivo.
57